Vol 55, No 5 (2024)
Editorial
Published online: 2024-10-31
Cladribine — still important in era of new therapies
DOI: 10.5603/ahp.103132
Acta Haematol Pol 2024;55(5):229-230.
Abstract
Not available
References
- Robak T. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006; 108(2): 473–479.
- Janowska A, Janus A, Robak T. New therapeutic options for hairy cell leukemia. Acta Haematologica Polonica. 2022; 53(1): 39–47.
- Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. Journal of Clinical Oncology. 2012; 30(20): 2441–2448.
- Libura M, Giebel S, Piatkowska-Jakubas B, et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood. 2016; 127(3): 360–362.
- Pluta A, Robak T, Brzozowski K, et al. Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). Leukemia & Lymphoma. 2019; 61(3): 588–603.
- Libura M, Bialopiotrowicz E, Giebel S, et al. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific Reports. 2021; 11(1).
- Brzozowski K, Pluta A, Włodarczyk M, et al. DAC and CLAM are equally effective as early second induction in newly diagnosed AML patients with persistent leukemia in early bone marrow evaluation – a retrospective analysis of Polish Adult Leukemia Group. Acta Haematologica Polonica. 2024.
- DiNardo C, Jonas B, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine. 2020; 383(7): 617–629.